

February 18, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir / Madam,

Sub: Clarification on news item appearing in "https://www.ndtvprofit.com/"

Ref: i) NSE email reference No.: NSE/CM/Surveillance/16477 dated February 18, 2026

ii) BSE email reference No.: L/SURV/ONL/RV/SG/ (2025-2026)/ 187 dated February 18, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to your email communication mentioned in the reference above, seeking clarifications on news item appearing in "https://www.ndtvprofit.com/", we submit the following:

The Company has been making timely and adequate disclosures of all material events and information to the stock exchanges in strict compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As intimated to the stock exchanges on February 10, 2026 with regard to completion of US FDA inspection at Unit-VII of Aurobindo Pharma Ltd, we would be responding to the US FDA within the stipulated timelines.

At present, there is no material event or information that requires further disclosure under Regulation 30 of the SEBI LODR Regulations, other than what has already been disclosed to the exchanges.

Moreover, we would like to submit that the Company routinely undergoes regulatory inspections across its manufacturing facilities by global regulatory authorities, including the USFDA, as part of normal business operations. Any observations issued during such inspections are addressed in accordance with established regulatory processes. Where required under applicable regulations, the Company makes appropriate disclosures to the stock exchanges in a timely manner.

We request you to kindly take the above information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithriviham, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com